Drugs / BNT329
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07186842 | Nov 2025 → May 2030 expected | high grade malignant neoplasm | BioNTech SE | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07186842 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT07186842 ↗ |